The article examines the objective, findings, and clinical context described in Looking Beyond Symptoms in Psychiatric Drug Development.
Approach:
Interview perspective: Tanya Wallace, PhD, AbbVie’s VP and Global Head of Neuroscience Discovery Research, discusses changes in psychiatric R&D.
Translational tools: The interview describes EEG, receptor-occupancy imaging, resting-state and task-based fMRI, fluid biomarkers, and computational methods used or explored to connect preclinical findings with human studies.
Biomarker validation: Preclinical comparisons of brain tissue, CSF, and plasma biomarkers, followed by complementary clinical measures such as receptor-occupancy studies, are described as ways to assess whether peripheral changes reflect central effects.
Key Findings:
Wallace says psychiatric R&D has shifted from reliance mainly on symptom clusters and clinical observations toward greater use of human genetics, circuit biology, and translational biomarkers.
EEG and imaging approaches are used or investigated to assess target engagement, support dose selection, and examine drug effects on brain activity and networks.
Computational and multimodal methods may help analyze clinical, imaging, EEG, and fluid-biomarker data and identify disease subgroups.
Wallace gives an immunometabolic profile in some people with depression, including elevated inflammatory cytokines and other inflammatory biomarkers, as an example of a potential subpopulation signal.
The interview notes that the relationship between peripheral biomarkers and brain disease requires validation.
Interpretation:
Wallace characterizes the field as having improved tools for studying psychiatric biology and patient heterogeneity, while emphasizing that substantial work remains.
Limitations:
This is an interview and does not report a clinical trial or systematic review.
The context provides no quantitative results or independent evaluation of the approaches discussed.
The relationship between blood-based biomarkers and processes in the brain remains an open question in the interview.
